Science at Sanofi

This video presents results from the Phase 4 VESTIGE trial, demonstrating how dupilumab improves airway structure and function in severe type 2 asthma. Using breakthrough Functional Respiratory Imaging technology, the study reveals structural improvements that conventional lung function tests may not detect.

The management of bullous pemphigoid is challenging and new treatment approaches are needed. Read this article to find out more.

Systemic corticosteroids and other immunosuppressants are the current mainstay of therapy but carry risks for patients with bullous pemphigoid. Read this article to find out more

In bullous pemphigoid, autoimmunity to BP180 and BP230 is thought to trigger a type 2 inflammatory response. Read this article to find out more

Many factors, including older age and multimorbidity, are associated with mortality in bullous pemphigoid. Read this article to find out more

The heterogeneous presentation of bullous pemphigoid may shed light on why patients are underdiagnosed. Read the article to learn more